Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-02-15

AUTHORS

Salmaan Kanji, Marc M. Perreault, Clarence Chant, David Williamson, Lisa Burry

ABSTRACT

BackgroundThe purpose of this study was to characterize the usage patterns and clinical outcomes of DAA in Ontario and Quebec over a 1-year period.MethodsAll hospitals with DAA on formulary in Ontario and Quebec were invited to participate. Consecutive patients who received DAA from 1 March 2003 to 29 February 2004 were identified retrospectively. Demographic, treatment, and outcome variables were collected via chart review. Descriptive statistics on relevant variables were performed, along with logistic regression to determine relevant risk factors for survival and bleeding.ResultsThirty-seven sites participated with a total of 261 courses of DAA administered. The overall mortality rate was 45%; age (> 65 years), multiple organ system failure (> 3), and nosocomial source of sepsis were predictors of mortality, whereas early DAA administration (< 12 h) was associated with lower mortality. Serious bleeding events occurred in 10% of the patients. Only 1 case (0.4%) of fatal intracranial bleed was observed. Multiple organ system failure (≥ 4)and relative contraindications to DAA were predictors of bleeding events.InterpretationMortality and bleeding complications associated with the use of DAA were higher than that reported in randomized trials but similar to other usage database. This may be due to the higher severity of illness seen in this cohort of patients. Modifiable risks associated with mortality and bleeding, such as time to treatment, and knowledge of relative contraindications should be targets of further research and future educational efforts in order to optimize the risk-to-benefit ratio of DAA. More... »

PAGES

517-523

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00134-007-0555-9

DOI

http://dx.doi.org/10.1007/s00134-007-0555-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1027669835

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17325837


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Infective Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Contraindications", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Utilization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug-Related Side Effects and Adverse Reactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemorrhage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Logistic Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multivariate Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ontario", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Product Surveillance, Postmarketing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein C", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quebec", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sepsis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Systemic Inflammatory Response Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, The Ottawa Hospital, Ottawa Health Research Institute, 501 Smyth Road, Room 1818, H1H 8L6, Ottawa, ON, Canada", 
          "id": "http://www.grid.ac/institutes/grid.412687.e", 
          "name": [
            "Department of Pharmacy, The Ottawa Hospital, Ottawa Health Research Institute, 501 Smyth Road, Room 1818, H1H 8L6, Ottawa, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kanji", 
        "givenName": "Salmaan", 
        "id": "sg:person.01207613372.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207613372.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Facult\u00e9 de Pharmacie, Pavillon Jean-Coutu, Universit\u00e9 de Montr\u00e9al, C.P. 6128, Succursale Centre-ville, H3C 3J7, Montr\u00e9al, Qu\u00e9bec, Canada", 
          "id": "http://www.grid.ac/institutes/grid.14848.31", 
          "name": [
            "Facult\u00e9 de Pharmacie, Pavillon Jean-Coutu, Universit\u00e9 de Montr\u00e9al, C.P. 6128, Succursale Centre-ville, H3C 3J7, Montr\u00e9al, Qu\u00e9bec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Perreault", 
        "givenName": "Marc M.", 
        "id": "sg:person.0772060673.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772060673.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St. Michael\u2019s Hospital, University of Toronto, 30 Bond Street, Room Q4036, M5B 1W8, Toronto, ON, Canada", 
          "id": "http://www.grid.ac/institutes/grid.415502.7", 
          "name": [
            "St. Michael\u2019s Hospital, University of Toronto, 30 Bond Street, Room Q4036, M5B 1W8, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chant", 
        "givenName": "Clarence", 
        "id": "sg:person.0673055064.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673055064.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "D\u00e9partement de pharmacie, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, 5400 Gouin ouest, H4J 1C5, Montr\u00e9al, Qu\u00e9bec, Canada", 
          "id": "http://www.grid.ac/institutes/grid.414056.2", 
          "name": [
            "D\u00e9partement de pharmacie, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, 5400 Gouin ouest, H4J 1C5, Montr\u00e9al, Qu\u00e9bec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Williamson", 
        "givenName": "David", 
        "id": "sg:person.01365714423.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365714423.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mount Sinai Hospital, 600 University Avenue, M5G 1X5, Toronto, ON, Canada", 
          "id": "http://www.grid.ac/institutes/grid.416166.2", 
          "name": [
            "Mount Sinai Hospital, 600 University Avenue, M5G 1X5, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burry", 
        "givenName": "Lisa", 
        "id": "sg:person.01362024562.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362024562.00"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2007-02-15", 
    "datePublishedReg": "2007-02-15", 
    "description": "BackgroundThe purpose of this study was to characterize the usage patterns and clinical outcomes of DAA in Ontario and Quebec over a\u00a01-year period.MethodsAll hospitals with DAA on formulary in Ontario and Quebec were invited to participate. Consecutive patients who received DAA from 1 March 2003 to 29 February 2004 were identified retrospectively. Demographic, treatment, and outcome variables were collected via chart review. Descriptive statistics on relevant variables were performed, along with logistic regression to determine relevant risk factors for survival and bleeding.ResultsThirty-seven sites participated with a\u00a0total of 261 courses of DAA administered. The overall mortality rate was 45%; age (>\u202f65 years), multiple organ system failure (>\u202f3), and nosocomial source of sepsis were predictors of mortality, whereas early DAA administration (<\u202f12\u202fh) was associated with lower mortality. Serious bleeding events occurred in 10% of the patients. Only 1 case (0.4%) of fatal intracranial bleed was observed. Multiple organ system failure (\u2265\u202f4)and relative contraindications to DAA were predictors of bleeding events.InterpretationMortality and bleeding complications associated with the use of DAA were higher than that reported in randomized trials but similar to other usage database. This may be due to the higher severity of illness seen in this cohort of patients. Modifiable risks associated with mortality and bleeding, such as time to treatment, and knowledge of relative contraindications should be targets of further research and future educational efforts in order to optimize the risk-to-benefit ratio of DAA.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00134-007-0555-9", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313639", 
        "issn": [
          "0342-4642", 
          "1432-1238"
        ], 
        "name": "Intensive Care Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "33"
      }
    ], 
    "keywords": [
      "multiple organ system failure", 
      "organ system failure", 
      "relative contraindication", 
      "courses of DAA", 
      "serious bleeding events", 
      "fatal intracranial bleed", 
      "use of DAAs", 
      "adult severe sepsis", 
      "multicenter observational study", 
      "predictors of mortality", 
      "cohort of patients", 
      "overall mortality rate", 
      "relevant risk factors", 
      "DAA administration", 
      "bleeding events", 
      "severe sepsis", 
      "chart review", 
      "drotrecogin alfa", 
      "consecutive patients", 
      "intracranial bleed", 
      "clinical outcomes", 
      "nosocomial source", 
      "randomized trials", 
      "modifiable risk", 
      "risk factors", 
      "observational study", 
      "mortality rate", 
      "future educational efforts", 
      "lower mortality", 
      "logistic regression", 
      "patients", 
      "outcome variables", 
      "benefit ratio", 
      "mortality", 
      "sepsis", 
      "bleeding", 
      "contraindications", 
      "DAA", 
      "higher severity", 
      "descriptive statistics", 
      "educational efforts", 
      "treatment", 
      "risk", 
      "predictors", 
      "further research", 
      "complications", 
      "failure", 
      "hospital", 
      "alfa", 
      "cohort", 
      "illness", 
      "bleed", 
      "administration", 
      "trials", 
      "severity", 
      "survival", 
      "outcomes", 
      "age", 
      "total", 
      "study", 
      "Ontario", 
      "events", 
      "review", 
      "regression", 
      "relevant variables", 
      "use", 
      "course", 
      "target", 
      "period", 
      "factors", 
      "system failure", 
      "database", 
      "cases", 
      "variables", 
      "rate", 
      "Quebec", 
      "purpose", 
      "patterns", 
      "usage patterns", 
      "sites", 
      "knowledge", 
      "ratio", 
      "time", 
      "statistics", 
      "efforts", 
      "research", 
      "source", 
      "usage database", 
      "order"
    ], 
    "name": "Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study", 
    "pagination": "517-523", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1027669835"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00134-007-0555-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17325837"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00134-007-0555-9", 
      "https://app.dimensions.ai/details/publication/pub.1027669835"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_442.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00134-007-0555-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00134-007-0555-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00134-007-0555-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00134-007-0555-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00134-007-0555-9'


 

This table displays all metadata directly associated to this object as RDF triples.

286 TRIPLES      20 PREDICATES      138 URIs      130 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00134-007-0555-9 schema:about N0090661bd9614c85a51ec6182eaf65b1
2 N00de7975541f4c5ba3073fe51b46d5b7
3 N0821c66ae44c43a59c815a7a1eb8561a
4 N090d2ab4d6054feb95754f5ce7d83314
5 N0f5d071d8f9b43aab72ffa1bf742d612
6 N122b85a2a58749c5acadfea2cf7752eb
7 N217e5ccf8db641ecb857374a5624b8a1
8 N2820d3a819784ddea822103c43745989
9 N2ae98cec768444b9a36aa49fd57fcf84
10 N2d7c55cb093c4ac481b7756e6926f1f1
11 N2d9d236684c046258955090061e05842
12 N48572b8709324fd3903a3631c7faa05f
13 N574efcdb958c499bb31776eace0ff160
14 N5a06d7ece8dd4ad393865917edf8cc09
15 N70b49f97c6054391a507ee4ea600d85c
16 N78e247f9938a467ea683f757ddee2dd9
17 N7fb1d717c5744a168fdd9a3513c1db22
18 N895c979c694044b1a0d9bcc24ca53f4f
19 N8c86812ab58240858d633a6f4003575e
20 N8efa1607708a40d8837ea23177110794
21 Nb2686afee7b54936819dc5c47190f483
22 Nce21364c0caf4ab18c2bbd3303c514a1
23 Nd202c7c18a6b442c94e3e7b31945c1f5
24 Nfe5ca5fc473d452eb12d22c0398f4d70
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author Nd32ac81d96b74be9a6fcf0a7ca0b2d51
28 schema:datePublished 2007-02-15
29 schema:datePublishedReg 2007-02-15
30 schema:description BackgroundThe purpose of this study was to characterize the usage patterns and clinical outcomes of DAA in Ontario and Quebec over a 1-year period.MethodsAll hospitals with DAA on formulary in Ontario and Quebec were invited to participate. Consecutive patients who received DAA from 1 March 2003 to 29 February 2004 were identified retrospectively. Demographic, treatment, and outcome variables were collected via chart review. Descriptive statistics on relevant variables were performed, along with logistic regression to determine relevant risk factors for survival and bleeding.ResultsThirty-seven sites participated with a total of 261 courses of DAA administered. The overall mortality rate was 45%; age (> 65 years), multiple organ system failure (> 3), and nosocomial source of sepsis were predictors of mortality, whereas early DAA administration (< 12 h) was associated with lower mortality. Serious bleeding events occurred in 10% of the patients. Only 1 case (0.4%) of fatal intracranial bleed was observed. Multiple organ system failure (≥ 4)and relative contraindications to DAA were predictors of bleeding events.InterpretationMortality and bleeding complications associated with the use of DAA were higher than that reported in randomized trials but similar to other usage database. This may be due to the higher severity of illness seen in this cohort of patients. Modifiable risks associated with mortality and bleeding, such as time to treatment, and knowledge of relative contraindications should be targets of further research and future educational efforts in order to optimize the risk-to-benefit ratio of DAA.
31 schema:genre article
32 schema:isAccessibleForFree false
33 schema:isPartOf N502ba10236534fbe98c86e290b640be2
34 Ndcce06f0d11a4f3d95097abbf214cd97
35 sg:journal.1313639
36 schema:keywords DAA
37 DAA administration
38 Ontario
39 Quebec
40 administration
41 adult severe sepsis
42 age
43 alfa
44 benefit ratio
45 bleed
46 bleeding
47 bleeding events
48 cases
49 chart review
50 clinical outcomes
51 cohort
52 cohort of patients
53 complications
54 consecutive patients
55 contraindications
56 course
57 courses of DAA
58 database
59 descriptive statistics
60 drotrecogin alfa
61 educational efforts
62 efforts
63 events
64 factors
65 failure
66 fatal intracranial bleed
67 further research
68 future educational efforts
69 higher severity
70 hospital
71 illness
72 intracranial bleed
73 knowledge
74 logistic regression
75 lower mortality
76 modifiable risk
77 mortality
78 mortality rate
79 multicenter observational study
80 multiple organ system failure
81 nosocomial source
82 observational study
83 order
84 organ system failure
85 outcome variables
86 outcomes
87 overall mortality rate
88 patients
89 patterns
90 period
91 predictors
92 predictors of mortality
93 purpose
94 randomized trials
95 rate
96 ratio
97 regression
98 relative contraindication
99 relevant risk factors
100 relevant variables
101 research
102 review
103 risk
104 risk factors
105 sepsis
106 serious bleeding events
107 severe sepsis
108 severity
109 sites
110 source
111 statistics
112 study
113 survival
114 system failure
115 target
116 time
117 total
118 treatment
119 trials
120 usage database
121 usage patterns
122 use
123 use of DAAs
124 variables
125 schema:name Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study
126 schema:pagination 517-523
127 schema:productId N1fb53ddc380f4d889b6836cac9b69c11
128 Ncbee281c680949e2ba91efbe757cf26a
129 Nf016c876bea0477cb8f5a79a899c820d
130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027669835
131 https://doi.org/10.1007/s00134-007-0555-9
132 schema:sdDatePublished 2022-08-04T16:56
133 schema:sdLicense https://scigraph.springernature.com/explorer/license/
134 schema:sdPublisher N65102898619447e4be694bf2bfb53a8b
135 schema:url https://doi.org/10.1007/s00134-007-0555-9
136 sgo:license sg:explorer/license/
137 sgo:sdDataset articles
138 rdf:type schema:ScholarlyArticle
139 N0090661bd9614c85a51ec6182eaf65b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Protein C
141 rdf:type schema:DefinedTerm
142 N00de7975541f4c5ba3073fe51b46d5b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Recombinant Proteins
144 rdf:type schema:DefinedTerm
145 N0821c66ae44c43a59c815a7a1eb8561a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Male
147 rdf:type schema:DefinedTerm
148 N090d2ab4d6054feb95754f5ce7d83314 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Drug Utilization
150 rdf:type schema:DefinedTerm
151 N0f5d071d8f9b43aab72ffa1bf742d612 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Drug-Related Side Effects and Adverse Reactions
153 rdf:type schema:DefinedTerm
154 N122b85a2a58749c5acadfea2cf7752eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Humans
156 rdf:type schema:DefinedTerm
157 N1fb53ddc380f4d889b6836cac9b69c11 schema:name pubmed_id
158 schema:value 17325837
159 rdf:type schema:PropertyValue
160 N217e5ccf8db641ecb857374a5624b8a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Sepsis
162 rdf:type schema:DefinedTerm
163 N2820d3a819784ddea822103c43745989 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Infusions, Intravenous
165 rdf:type schema:DefinedTerm
166 N2a522f951d2449529d75bddd1161137b rdf:first sg:person.0673055064.37
167 rdf:rest Ne1800f4d84b040fca7f56db3b2035028
168 N2ae98cec768444b9a36aa49fd57fcf84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Systemic Inflammatory Response Syndrome
170 rdf:type schema:DefinedTerm
171 N2b4dc10a6ce54365872fe56f0a6d3a67 rdf:first sg:person.0772060673.93
172 rdf:rest N2a522f951d2449529d75bddd1161137b
173 N2d7c55cb093c4ac481b7756e6926f1f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Hemorrhage
175 rdf:type schema:DefinedTerm
176 N2d9d236684c046258955090061e05842 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Multivariate Analysis
178 rdf:type schema:DefinedTerm
179 N48572b8709324fd3903a3631c7faa05f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Middle Aged
181 rdf:type schema:DefinedTerm
182 N502ba10236534fbe98c86e290b640be2 schema:volumeNumber 33
183 rdf:type schema:PublicationVolume
184 N574efcdb958c499bb31776eace0ff160 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Contraindications
186 rdf:type schema:DefinedTerm
187 N5a06d7ece8dd4ad393865917edf8cc09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Ontario
189 rdf:type schema:DefinedTerm
190 N65102898619447e4be694bf2bfb53a8b schema:name Springer Nature - SN SciGraph project
191 rdf:type schema:Organization
192 N70b49f97c6054391a507ee4ea600d85c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Survival Analysis
194 rdf:type schema:DefinedTerm
195 N78e247f9938a467ea683f757ddee2dd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Logistic Models
197 rdf:type schema:DefinedTerm
198 N7fb1d717c5744a168fdd9a3513c1db22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Treatment Outcome
200 rdf:type schema:DefinedTerm
201 N895c979c694044b1a0d9bcc24ca53f4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Anti-Infective Agents
203 rdf:type schema:DefinedTerm
204 N8c86812ab58240858d633a6f4003575e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Product Surveillance, Postmarketing
206 rdf:type schema:DefinedTerm
207 N8efa1607708a40d8837ea23177110794 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Female
209 rdf:type schema:DefinedTerm
210 N9b1188ec8af44b919c961126f98b97dc rdf:first sg:person.01362024562.00
211 rdf:rest rdf:nil
212 Nb2686afee7b54936819dc5c47190f483 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Retrospective Studies
214 rdf:type schema:DefinedTerm
215 Ncbee281c680949e2ba91efbe757cf26a schema:name doi
216 schema:value 10.1007/s00134-007-0555-9
217 rdf:type schema:PropertyValue
218 Nce21364c0caf4ab18c2bbd3303c514a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Aged
220 rdf:type schema:DefinedTerm
221 Nd202c7c18a6b442c94e3e7b31945c1f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Quebec
223 rdf:type schema:DefinedTerm
224 Nd32ac81d96b74be9a6fcf0a7ca0b2d51 rdf:first sg:person.01207613372.27
225 rdf:rest N2b4dc10a6ce54365872fe56f0a6d3a67
226 Ndcce06f0d11a4f3d95097abbf214cd97 schema:issueNumber 3
227 rdf:type schema:PublicationIssue
228 Ne1800f4d84b040fca7f56db3b2035028 rdf:first sg:person.01365714423.46
229 rdf:rest N9b1188ec8af44b919c961126f98b97dc
230 Nf016c876bea0477cb8f5a79a899c820d schema:name dimensions_id
231 schema:value pub.1027669835
232 rdf:type schema:PropertyValue
233 Nfe5ca5fc473d452eb12d22c0398f4d70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
234 schema:name Severity of Illness Index
235 rdf:type schema:DefinedTerm
236 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
237 schema:name Medical and Health Sciences
238 rdf:type schema:DefinedTerm
239 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
240 schema:name Clinical Sciences
241 rdf:type schema:DefinedTerm
242 sg:journal.1313639 schema:issn 0342-4642
243 1432-1238
244 schema:name Intensive Care Medicine
245 schema:publisher Springer Nature
246 rdf:type schema:Periodical
247 sg:person.01207613372.27 schema:affiliation grid-institutes:grid.412687.e
248 schema:familyName Kanji
249 schema:givenName Salmaan
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207613372.27
251 rdf:type schema:Person
252 sg:person.01362024562.00 schema:affiliation grid-institutes:grid.416166.2
253 schema:familyName Burry
254 schema:givenName Lisa
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362024562.00
256 rdf:type schema:Person
257 sg:person.01365714423.46 schema:affiliation grid-institutes:grid.414056.2
258 schema:familyName Williamson
259 schema:givenName David
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365714423.46
261 rdf:type schema:Person
262 sg:person.0673055064.37 schema:affiliation grid-institutes:grid.415502.7
263 schema:familyName Chant
264 schema:givenName Clarence
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673055064.37
266 rdf:type schema:Person
267 sg:person.0772060673.93 schema:affiliation grid-institutes:grid.14848.31
268 schema:familyName Perreault
269 schema:givenName Marc M.
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772060673.93
271 rdf:type schema:Person
272 grid-institutes:grid.14848.31 schema:alternateName Faculté de Pharmacie, Pavillon Jean-Coutu, Université de Montréal, C.P. 6128, Succursale Centre-ville, H3C 3J7, Montréal, Québec, Canada
273 schema:name Faculté de Pharmacie, Pavillon Jean-Coutu, Université de Montréal, C.P. 6128, Succursale Centre-ville, H3C 3J7, Montréal, Québec, Canada
274 rdf:type schema:Organization
275 grid-institutes:grid.412687.e schema:alternateName Department of Pharmacy, The Ottawa Hospital, Ottawa Health Research Institute, 501 Smyth Road, Room 1818, H1H 8L6, Ottawa, ON, Canada
276 schema:name Department of Pharmacy, The Ottawa Hospital, Ottawa Health Research Institute, 501 Smyth Road, Room 1818, H1H 8L6, Ottawa, ON, Canada
277 rdf:type schema:Organization
278 grid-institutes:grid.414056.2 schema:alternateName Département de pharmacie, Hôpital du Sacré-Coeur de Montréal, 5400 Gouin ouest, H4J 1C5, Montréal, Québec, Canada
279 schema:name Département de pharmacie, Hôpital du Sacré-Coeur de Montréal, 5400 Gouin ouest, H4J 1C5, Montréal, Québec, Canada
280 rdf:type schema:Organization
281 grid-institutes:grid.415502.7 schema:alternateName St. Michael’s Hospital, University of Toronto, 30 Bond Street, Room Q4036, M5B 1W8, Toronto, ON, Canada
282 schema:name St. Michael’s Hospital, University of Toronto, 30 Bond Street, Room Q4036, M5B 1W8, Toronto, ON, Canada
283 rdf:type schema:Organization
284 grid-institutes:grid.416166.2 schema:alternateName Mount Sinai Hospital, 600 University Avenue, M5G 1X5, Toronto, ON, Canada
285 schema:name Mount Sinai Hospital, 600 University Avenue, M5G 1X5, Toronto, ON, Canada
286 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...